$RETA News

Last published 3y ago

3y agoBIIB RETABiogen Completes Acquisition of Reata PharmaceuticalsGlobeNewswireReata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26,
3y agoRETAReata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.Business WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases,
3y agoAMED DBTX RETA SURFMoore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law FirmGlobeNewswireNEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoDEN INPX RETA TALSMoore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law FirmGlobeNewswireNEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoINTC ROKU NYCB BIIB+8Stocks making the biggest moves midday: Intel, Roku, Sweetgreen, Ford and moreCNBCCheck out the companies making headlines in midday trading.
3y agoINTC ROKU BIIB RETA+13Stocks making the biggest moves premarket: Intel, Roku, Procter & Gamble and moreCNBCThese are the stocks posting the largest moves in premarket trading.
3y agoBIIB RETABiogen to Acquire Reata PharmaceuticalsGlobeNewswireSKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich's ataxia Proposed acquisition represents meaningful step forward in Biogen's strategy for sustainable growth,
3y agoRETAReata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich's AtaxiaBusiness WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases,
3y agoRETAAn Open-label, Single Sequence, 2-period Crossover DDI Study of Omaveloxolone in Healthy Subjects - NCT05909644ClinicalTrials.govMaximum concentration (Cmax) of omaveloxolone, Area under the plasma concentration-time curve from 0 to tlast (AUC0-tlas) of omaveloxolone, Area under the plasma concentration-time curve from 0 extrapolated to infinity (AUC0-∞) of omaveloxolone
3y agoRETAReata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval SupplementBusiness WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases,
3y agoRETAReata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development OfficerBusiness WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases,
3y agoRETARETA ALERT: The Law Offices of Vincent Wong Investigate Reata Pharmaceuticals, Inc. for Potential Violations of Securities LawsPR NewswireNEW YORK, June 12, 2023 /PRNewswire/ -- Attention Reata Pharmaceuticals, Inc. ("Reata") (NASDAQ:RETA) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Reata and
3y agoRETARETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities LawsPR NewswireNEW YORK, June 9, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) To be
3y agoRETAA Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) - NCT05895552ClinicalTrials.govMeasure the change from baseline in average pain intensity as assessed by the Numeric Pain Rating Scale (NPRS), Count of reported adverse events
3y agoRETAReata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare ConferenceBusiness WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases,
3y agoRETARETA ALERT: The Law Offices of Vincent Wong Investigate Reata Pharmaceuticals, Inc. for Potential Violations of Securities LawsPR NewswireNEW YORK, June 5, 2023 /PRNewswire/ -- Attention Reata Pharmaceuticals, Inc. ("Reata") (NASDAQ:RETA) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Reata and
3y agoRETARETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities LawsPR NewswireNEW YORK, June 2, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) To be
3y agoRETARETA NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.PR NewswireNEW YORK, May 31, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Reata Pharmaceuticals, Inc. ("Reata") (NASDAQ:RETA) violated federal securities laws. CURRENT
3y agoRETARETA ALERT: The Law Offices of Vincent Wong Investigate Reata Pharmaceuticals, Inc. for Potential Violations of Securities LawsPR NewswireNEW YORK, May 31, 2023 /PRNewswire/ -- Attention Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASDAQ:RETA) shareholders: The Law Offices of Vincent Wong announce that an investigation has
3y agoRETARETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities LawsPR NewswireNEW YORK, May 30, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) To be
3y agoRETARETA NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.PR NewswireNEW YORK, May 29, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASDAQ:RETA) violated federal
3y agoRETAReata Pharmaceuticals, Inc. (RETA) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoRETAReata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development ProgramsBusiness WireSKYCLARYS® Approved by FDA in the U.S. Approximately 500 Patient Start Forms Received for SKYCLARYS Marketing Authorization Application for Omaveloxolone in Europe Under Review Announced $275 Million Debt
3y agoRETAReata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023Business WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical, company focused on developing and commercializing novel therapies for patients with severe diseases,
3y agoRETAReata Pharmaceuticals Announces Participation in the Barclays Global Healthcare ConferenceBusiness WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases,
3y agoRETAReata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich's AtaxiaBusiness WireFRIEDREICH'S ATAXIA IS AN ULTRA-RARE, PROGRESSIVE, NEUROMUSCULAR DISEASE THAT AFFECTS APPROXIMATELY 5,000 DIAGNOSED PATIENTS IN THE UNITED STATES SKYCLARYS IS INDICATED FOR THE TREATMENT OF FRIEDREICH'S ATAXIA IN
3y agoRETAApproval of Skyclarys, Nda #216718 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 02/28/2023; Drug Name: Skyclarys, Nda #216718; Active Ingredients: OMAVELOXOLONE; Company: Reata Pharmaceuticals Inc; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 216718
4y agoRETAReata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare ConferenceBusiness WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced that management will participate in the Guggenheim 2022 Immunology & Neurology
4y agoRETAReata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development ProgramsBusiness WireNDA for Omaveloxolone for Patients With Friedreich's Ataxia Under Review With PDUFA Date of February 28, 2023 FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the Omaveloxolone NDA and the Late Cycle
4y agoRETAReata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022Business WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the third quarter ended
4y agoRETAReata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022Business WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for omaveloxolone and disease education
4y agoRETAReata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich's AtaxiaBusiness WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration ("FDA") has informed the Company
4y agoRETAMoore Kuehn, PLLC Encourages Investors of Reata Pharmaceuticals, Inc. to Contact Law FirmGlobeNewswireNEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) breached their fiduciary duties to shareh
4y agoRETAReata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma ConferenceBusiness WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced that management will participate in investor meetings at the Citi 17th Annual BioPharma Conference on September 7 ��
4y agoRETAReata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich's AtaxiaBusiness WireReata Submitted New Data and Analyses to Address FDA Questions During Mid-Cycle Meeting FDA Extended PDUFA Date to Provide Time for Full Review of New Submissions PDUFA Date Extended to February 28, 2023 Reata Pharmaceuticals, Inc. (NASDAQ:RETA
4y agoRETAReata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development ProgramsBusiness WireReceived Priority Review and Acceptance for Filing of the NDA for Omaveloxolone for Treatment of Patients with Friedreich's Ataxia Provides Update from FDA Mid-Cycle Communication Meeting on Omaveloxolone for Patients with Friedreich's Ataxia Anno
4y agoRETAReata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022Business WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the second quarter ended June 30, 2022, and provide an update
4y agoRETAReata Announces the Appointment of Steven W. Ryder, M.D. to its Board of DirectorsBusiness WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022. "We are thrilled to
4y agoRETAReata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich's AtaxiaBusiness WireFriedreich's Ataxia is a Rare, Progressive, Life-Shortening, Neuromuscular Disease that Affects Approximately 5,000 Patients in the United States Application Assigned a PDUFA Date of November 30, 2022 If Approved, Omaveloxolone Would Become the Fi
4y agoRETAReata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development ProgramsBusiness WireCompleted Rolling Submission of NDA for Omaveloxolone for Treatment of Patients with Friedreich's Ataxia; Actively Preparing for Commercial Launch Updates Outcome of Type A Meeting with the FDA on the Protocol Amendment for FALCON Reaffirms Cash R
4y agoRETAReata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022Business WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2022, and provide an update
4y agoALEC AXSM PTCT RETAMoore Kuehn, PLLC Encourages Investors of ALEC, RETA, ASXM, and PTCT to Contact Law FirmGlobeNewswireNEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ:ALEC), Reata Pharmaceuticals, Inc. (NASDAQ:RETA), Axsome Ther
4y agoRETAReata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich's AtaxiaBusiness WireIf Approved, Omaveloxolone Would Become the First Therapy Indicated for the Treatment of Patients with Friedreich's Ataxia Friedreich's Ataxia Affects Approximately 5,000 Patients in the United States with an Estimated 4,000 Diagnosed Patients Rea
4y agoGDOT PGNY PTCT RETAMoore Kuehn, PLLC Encourages Investors of PGNY, PTCT, GDOT, and RETA to Contact Law FirmGlobeNewswireNEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Progyny, Inc. (NASDAQ:PGNY), PTC Therapeutics, Inc. (NASDAQ:PTCT), Green Dot Corpor
4y agoRETAReata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development ProgramsBusiness WireInitiated Rolling Submission of NDA for Omaveloxolone for Treatment of Patients with Friedreich's Ataxia; Actively Preparing for Commercial Launch Updated Cash Guidance - Sufficient to Fund Operations Through End of 2024 Conference Call with Manag
4y agoRETAReata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport SyndromeBusiness WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," or "we"), today announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter ("CRL") regarding the New Drug Application ("NDA") for bardoxolone meth
4y agoRETAReata Pharmaceuticals, Inc. To Report Fourth Quarter and Full Year 2021 Financial Results and To Provide an Update on Development Programs on February 28, 2022Business WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on the Company's business operations and cl
4y agoRETAReata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich's AtaxiaBusiness WirePlans to Complete Submission by the End of the First Quarter of 2022 If Approved, Omaveloxolone Would Become the First Therapy Indicated for the Treatment of Patients with Friedreich's Ataxia Reata Pharmaceuticals, Inc. (NASDAQ:RETA), ("Reata," th
4y agoRETAREATA PHARMACEUTICALS, INC. - Appeal, AffirmedUS Patent Trial and Appeal Board
4y agoRETAReata Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting of Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport SyndromeBusiness WireReata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," or "we"), today announced the outcome of the U.S. Food and Drug Administration ("FDA") Cardiovascular and Renal Drugs Advisory Committee ("Committee") meeting on bardoxolone methyl ("bar